Single-Cell Profiling of ANKRD26 Thrombocytopenia Reveals Progenitor Expansion and Polyploid Apoptosis via JUNB-p21
ANKRD26-related thrombocytopenia (THC2) is a rare inherited platelet disorder caused by germline variants in the 5' untranslated region (UTR) of ANKRD26. While prior studies using in vitro models or isolated case reports have suggested impaired megakaryopoiesis as a central mechanism, detailed insights have remained elusive-primarily due to the rarity, fragility, and heterogeneity of megakaryocytes. Here, we present a comprehensive, cross-validated analysis of bone marrow samples from four independent THC2 patients, integrating single-cell transcriptomics and ex vivo functional profiling. Across all patients, we analyzed CD34⁺ hematopoietic stem and progenitor cells (HSPCs) (47,281 THC2-HSPCs vs. 51,907 control cells) and primary megakaryocytes (pMKs) (7,309 THC2-pMKs vs. 5,077 controls), uncovering a consistent pattern of megakaryocyte progenitors (MkP) expansion and a marked reduction in polyploid megakaryocytes-indicating a conserved pathophysiologic phenotype. In our index patient, we identified the 5'UTR single-nucleotide variant in ANKRD26 that led to significantly elevated expression across four megakaryocyte-lineage subsets-spanning multipotent progenitors, common myeloid progenitors, megakaryocyte-erythroid progenitors, and MkPs-as well as in terminally enriched pMKs. Spatial transcriptomics and confocal imaging localized ANKRD26 to the centrosome, implicating it in mitotic regulation during megakaryocyte maturation. Mechanistically, we discovered that elevated ANKRD26 induces apoptosis in polyploid megakaryocytes via JUNB-mediated transcriptional activation of CDKN1A (p21)-operating independently of the canonical p53-PIDDosome axis. This multi-patient study provides the most comprehensive cellular and molecular portrait of ANKRD26-driven thrombocytopenia to date, offering novel insights into defective megakaryopoiesis and identifying candidate therapeutic targets to restore platelet production.
Authors
- T YU
- Xiaofan Liu (ORCID: https://orcid.org/0000-0002-9911-4491)
- Jiuxuan Li (ORCID: https://orcid.org/0000-0003-2080-4025)
- Wei Xu (ORCID: https://orcid.org/0000-0001-6774-6366)
- Xiaojie Wang (ORCID: https://orcid.org/0000-0002-3204-3764)
- Wei Zhang (ORCID: https://orcid.org/0000-0001-7800-3189)
- Lin Cai
- Lixin Xiang
- Heng Yang (ORCID: https://orcid.org/0000-0002-6447-2985)
- Maoshan Chen (ORCID: https://orcid.org/0000-0002-3827-4969)
- Wuchen Yang
- Xiaoting Yin
- Calvin Li
- Lin Chen
- Qian Ran
- Wanling Gou
- Lanyue Hu
- Renchi Yang
- Zhongjun Li
- Xiaoliang Li
- Yangzhou Jiang
- Chengning Tan
- Yangyang Zhang
Institutions
- Army Medical University (CN)
- Dalian Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- University of California, Irvine (US)
- University of California, Irvine Medical Center (US)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Tianjin Institute of Industrial Biotechnology (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Blood
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1182/blood.2025030017
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00